Summary by Moomoo AI
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, was the subject of a Schedule 13G/A filing with the Securities and Exchange Commission (SEC) on September 30, 2024, indicating a change in ownership by several related investment entities. Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., Cubist Systematic Strategies, LLC, and Steven A. Cohen collectively reported shared voting and dispositive power over 247,055 shares of Arcutis Biotherapeutics, representing 0.2% of the company's class of common stock. The filing, signed by authorized person Jason M. Colombo, clarifies that none of the reporting persons directly own shares but have investment and voting power through managed funds. The address for Point72 Asset Management, Point72 Capital Advisors, and Mr. Cohen is in Stamford, CT, while Cubist Systematic Strategies is located in New York, NY. All entities are organized under Delaware law, with Mr. Cohen being a U.S. citizen. The filing also indicates that the reporting persons do not have an intention to change or influence the control of Arcutis Biotherapeutics.
